152 related articles for article (PubMed ID: 24443104)
41. Primary liver carcinoma arising in people younger than 30 years.
Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
[TBL] [Abstract][Full Text] [Related]
42. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
[TBL] [Abstract][Full Text] [Related]
43. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.
Murakami Y; Yasuda T; Saigo K; Urashima T; Toyoda H; Okanoue T; Shimotohno K
Oncogene; 2006 Apr; 25(17):2537-45. PubMed ID: 16331254
[TBL] [Abstract][Full Text] [Related]
44. Fibrolamellar hepatocellular carcinoma: current clinical perspectives.
Lafaro KJ; Pawlik TM
J Hepatocell Carcinoma; 2015; 2():151-7. PubMed ID: 27508204
[TBL] [Abstract][Full Text] [Related]
45. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression.
Breuhahn K; Vreden S; Haddad R; Beckebaum S; Stippel D; Flemming P; Nussbaum T; Caselmann WH; Haab BB; Schirmacher P
Cancer Res; 2004 Sep; 64(17):6058-64. PubMed ID: 15342387
[TBL] [Abstract][Full Text] [Related]
46. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma.
Moreno-Luna LE; Arrieta O; García-Leiva J; Martínez B; Torre A; Uribe M; León-Rodríguez E
BMC Cancer; 2005 Oct; 5():142. PubMed ID: 16259635
[TBL] [Abstract][Full Text] [Related]
47. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
48. Gene expression signature of human HepG2 cell line.
Costantini S; Di Bernardo G; Cammarota M; Castello G; Colonna G
Gene; 2013 Apr; 518(2):335-45. PubMed ID: 23357223
[TBL] [Abstract][Full Text] [Related]
49. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
50. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
[TBL] [Abstract][Full Text] [Related]
51. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.
Buckley AF; Burgart LJ; Kakar S
Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914
[TBL] [Abstract][Full Text] [Related]
52. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].
Shen HW; Wu YL; Peng SY
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749
[TBL] [Abstract][Full Text] [Related]
53. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma.
Xu L; Hui L; Wang S; Gong J; Jin Y; Wang Y; Ji Y; Wu X; Han Z; Hu G
Cancer Res; 2001 Apr; 61(7):3176-81. PubMed ID: 11306505
[TBL] [Abstract][Full Text] [Related]
54. Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver.
Lee TY; Kim KT; Han SY
Korean J Hepatol; 2007 Mar; 13(1):70-80. PubMed ID: 17380077
[TBL] [Abstract][Full Text] [Related]
55. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.
Cantarini MC; de la Monte SM; Pang M; Tong M; D'Errico A; Trevisani F; Wands JR
Hepatology; 2006 Aug; 44(2):446-57. PubMed ID: 16871543
[TBL] [Abstract][Full Text] [Related]
56. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
57. Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma.
Ehrenfried JA; Zhou Z; Thompson JC; Evers BM
Ann Surg; 1994 Oct; 220(4):484-9; discussion 489-91. PubMed ID: 7944660
[TBL] [Abstract][Full Text] [Related]
58. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
Abdelhamed W; El-Kassas M
World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
[TBL] [Abstract][Full Text] [Related]
59. Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study.
Ramai D; Ofosu A; Lai JK; Gao ZH; Adler DG
Dig Dis Sci; 2021 Jan; 66(1):308-314. PubMed ID: 32052215
[TBL] [Abstract][Full Text] [Related]
60. Non coding RNA analysis in fibrolamellar hepatocellular carcinoma.
Farber BA; Lalazar G; Simon EP; Hammond WJ; Requena D; Bhanot UK; La Quaglia MP; Simon SM
Oncotarget; 2018 Feb; 9(12):10211-10227. PubMed ID: 29535801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
